Dr. Jack West, Swedish Cancer Institute, discusses current trials seeking to determine the efficacy of combining immunotherapy agents in lung cancer.
Dr. Jack West, Swedish Cancer Institute, raises the question of whether to use immune checkpoint inhibitors as first-line treatment of lung cancer, alone or in combination with chemotherapy.
Dr. Jed Gorden, Swedish Cancer Institute, reviews the lung cancer screening process, including low-dose CT scanning, smoking cessation, follow-up testing and counseling, and describes the potential benefits.
Dr. Jed Gorden, Swedish Cancer Institute, describes the differences between bronchoscopy and endobronchial ultrasound, highlighting the advantages of EBUS in diagnosis and staging.
Dr. Jack West, Swedish Cancer Institute, defines maintenance therapy in advanced NSCLC and discusses maintenance treatment strategies.
There is still time! Register for the Targeted Therapies Patient Forum this Saturday, September 12, 2020! Register Now!
There is still time! Register for the Targeted Therapies Patient Forum this Saturday, September 12, 2020! Register Now!
Covid-19 Financial Impacts and Resources for the Cancer Patient As many of you know, the costs of treating a new disease or virus are often...
Covid-19 Financial Impacts and Resources for the Cancer Patient As many of you know, the costs of treating a new disease or virus are often...
GRACE is pleased to announce the acceptance of four rising stars in to the second year of the GRACE Patient Education Ambassador Program for the 2020...
There is a wealth of info in these videos with panels of specialists discussing the benefits vs side effects and how they fit into individual...
AfterCT, tissue biopsy and pet scan, I was diagnosed as stage 1 b lung non small adenocacinoma, exon19 deletion EGFR mutation and TP53 mutation. When...
I am a 63 yr old non smoker. I had breast cancer 20 yrs ago. Chemo radiation and have been doing well . I recently have pain in the base of my neck...
I need information on adrenal metastasis from multifocal nsclc. Initial dx march 2019 surgical lobectomy complications eventually had to undergo...
When there is evidence of successful therapy of EGFR with TKI in one area of the lung but suggestion of progression in another area, what is the next...
Dr. Nathan Pennell, Cleveland Clinic, evaluates chemotherapy sensitivity assays, describing the difficulties inherent in predicting response to chemotherapy agents.
Dr. Nathan Pennell, Cleveland Clinic, describes treatment of NSCLC patients with HER2 mutations using agents such as Gilotrif or Herceptin.
Dr. Nathan Pennell, Cleveland Clinic, discusses acquired resistance to Xalkori in ALK-positive patients, and second generation inhibitors designed to overcome that resistance, such as Zykadia and alectinib.
Dr. Nathan Pennell, Cleveland Clinic, describes other options for treatment of acquired resistance, including chemotherapy, ablation with SBRT and a combination of Gilotrif and Erbitux.
Dr. Nathan Pennell, Cleveland Clinic, discusses the concept of acquired resistance and new agents designed to address it, including Rociletinib and Merelitinib.
Dr. Nathan Pennell, Cleveland Clinic, reviews the available trial evidence for the use of targeted therapies in the post-operative/adjuvant setting.
Dr. Mark Socinski, University of Pittsburgh Medical Center, discusses the benefits of giving two additional cycles of chemotherapy in combination with radiotherapy for stage III NSCLC.
Dr. Mark Socinski, University of Pittsburgh Medical Center, describes strategies for treatment of the elderly and frail patient with locally advanced NSCLC.
Dr. Mark Socinski, University of Pittsburgh Medical Center, discusses the factors to consider in defining resectability in stage IIIa lung cancer.
Dr. Mark Socinski, University of Pittsburgh Medical Center, compares the use of chemotherapy to chemo/radiation in the preoperative setting in stage IIIA lung cancer.
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.